Free Trial
OTCMKTS:BSTGD

(BSTGD) (BSTGD) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.51
$2.99
50-Day Range
N/A
52-Week Range
$0.60
$17.40
Volume
10,234 shs
Average Volume
25,636 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About (BSTGD)

Biostage, Inc. is a biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. It operates through Cellframe technology, engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. The company was founded on May 3, 2012 and is headquartered in Holliston, MA.

BSTGD Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive BSTGD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (BSTGD) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/11/2017
Today
5/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:BSTGD
Previous Symbol
NASDAQ:BSTG
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Hong Yu
    President
  • Shun Fu Hu
    VP-Business Development & Operations
  • Peter A. Pellegrino
    Chief Financial & Accounting Officer
  • William Fodor
    Chief Scientific Officer

BSTGD Stock Analysis - Frequently Asked Questions

How were (BSTGD)'s earnings last quarter?

(BSTGD) (OTCMKTS:BSTGD) issued its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.09.

This page (OTCMKTS:BSTGD) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners